Tag Archives: patent

Is the Polio Vaccine an Anti-Patent Success Story?

polio-vaccine

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization Question from a Reader: Heather: Whether Jonas Salk believed in patenting research or not isn’t important, at least not to me. What I do find important, and hadn’t realized until reading this article, is that the polio vaccine was extremely successful despite the fact that it wasn’t patented. That sounds like an interesting story because it goes against the current dogma of ‘we won’t Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Managing in a Cost-Constrained Environment

medicine-thumb

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

The Real Reason Why Salk Refused to Patent the Polio Vaccine

Vaccine

Editor’s Note: Despite the progress in polio and other diseases made possible by vaccines, today we are witnessing a resurgence of vaccine-preventable illnesses as nervous parents skip their children’s shots. Watch the PBS documentary Vaccines—Calling the Shots to find learn more.  BIO is also a leading voice on the patent-ability of biotech inventions and other IP matters. To get the most recent updates on IP in the biotech world, please sign up for BIO’s free bi-monthly IP Newsletter. Read More >

Patently BIOtech  |  24 Comments  |  Email This Post
Tags: , , , , , , ,

Brazilian Innovation: A Patent Success

plant

The story of Acheflan highlights the role of patents in homegrown innovation in developing countries.  Professor Michael Ryan of George Washington University Law School reviewed several case studies (including Acheflan) in Brazil that highlight the differences in biomedical innovation both pre- and post-intellectual property reforms. In the early 1980’s, Ache Laboratorios Farmaceuticos (a Brazilian generics manufacturer) became aware of a plant that grew near coastal cities that local fishermen would mash into an oil rub Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Exclusive Licenses Do Not Discourage Follow On Research

medical_research_thumb

A recent study presented at the Patent Statistics for Decision Makers Conference organized at the United States Patent Office questions the logic behind a nonexclusive license preference often found in U.S. government technology transfer policy. In “The Role of Exclusive Licensing in Follow-on Research of Academic Patented Inventions” presentation the authors demonstrate that, contrary to the belief by some, exclusive licensing does not impede future research. The authors ask two questions.  First, does exclusive licensing affect licensee follow-on research?  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,